Medipsych S.A.
- Address
- Megalou Alexandrou 82, 713 05 Irakleio, Greece
Medipsych S.A. - Schizophrenia Research Center
Medipsych S.A. is a specialized clinical research facility dedicated to advancing the understanding and treatment of severe mental health disorders. The center demonstrates particular expertise in conducting long-term safety studies and extension trials, providing critical data on the sustained effects of novel therapeutic interventions in psychiatric populations.
- Cognitive impairment associated with schizophrenia
- Long-term safety and tolerability assessment of investigational psychiatric medications
- Phase III clinical trial program participation in schizophrenia treatment
The center's current research portfolio includes innovative studies examining Iclepertin, an investigational treatment targeting cognitive deficits in schizophrenia. As part of the comprehensive CONNEX clinical trial program, Medipsych S.A. contributes valuable long-term safety data by following patients beyond the initial treatment period, ensuring thorough evaluation of therapeutic outcomes and patient well-being over extended timeframes.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Medipsych S.A.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Long-term Safety Evaluation of Iclepertin in Schizophrenia Patients Post-Completion of Phase III Trials | Boehringer Ingelheim International GmbH | Phase III | Not Recruiting | Mar 2022 | Jan 2025 |
IMP list
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Iclepertin | 1 | Unknown | 2022-03-29 | 2022-03-29 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.